8-K: Tempus AI Q2 Revenue Soars 89.6%, Boosts 2025 Outlook

Tempus AI reported robust second-quarter 2025 financial results, with revenue surging 89.6% year-over-year and significantly improving its full-year 2025 financial guidance.

Summary

• Revenue for the second quarter ended June 30, 2025, increased 89.6% year-over-year to $314.6 million.
• Genomics revenue grew 115.3% year-over-year to $241.8 million, driven by accelerating volume growth in Oncology (26%) and Hereditary (32%) testing.
• Data and services revenue increased 35.7% year-over-year to $72.8 million, with Insights (data licensing) growing 40.7%.
• Gross profit for the quarter was $195.0 million, a 158.3% year-over-year increase.
• Net loss significantly improved to ($42.8 million) in Q2 2025, compared to ($552.2 million) in Q2 2024.
• Adjusted EBITDA improved by $25.6 million year-over-year, reaching ($5.6 million) in Q2 2025 compared to ($31.2 million) in Q2 2024.
• Full-year 2025 revenue guidance was increased to approximately $1.26 billion, representing about 82% annual growth.
• Full-year 2025 Adjusted EBITDA guidance was raised to $5 million, an improvement of approximately $110 million over 2024.
• The company completed an upsized offering of $750 million in 0.75% convertible senior notes just after quarter end, enhancing financial flexibility.
• Cash and marketable securities stood at $293.0 million at quarter end, an improvement of approximately $70 million from the previous quarter.
• Clinical volumes re-accelerated, growing 30% in the quarter, with over 212,000 NGS tests delivered.
• Expanded AI-powered clinical tools, including extending Tempus Next into breast cancer and integrating Tempus One into leading EHR systems.
• Introduced Tempus xM for treatment and response monitoring (TRM), a liquid biopsy assay, and expanded collaboration with Personalis for colorectal cancer MRD.
• Reached a database milestone of over 40 million clinical patient records, with approximately 9 million de-identified and ingested, spanning approximately 1.1 billion healthcare documents and 4 million sequenced samples, totaling over 350 petabytes of data.

Sentiment

Score: 9

Explanation: The filing indicates very strong financial performance with significant revenue growth, substantial improvement in profitability metrics (net loss and Adjusted EBITDA), and a positive upward revision of full-year guidance. Operational highlights also demonstrate continued innovation and market expansion. The successful convertible notes offering further strengthens the balance sheet.

Positives

• Revenue increased 89.6% year-over-year to $314.6 million in Q2 2025.
• Genomics revenue surged 115.3% year-over-year to $241.8 million.
• Oncology testing volume grew 26% and Hereditary testing volume grew 32%.
• Data and services revenue increased 35.7% year-over-year to $72.8 million, with Insights growing 40.7%.
• Gross profit increased 158.3% year-over-year to $195.0 million.
• Net loss significantly improved to ($42.8 million) from ($552.2 million) year-over-year.
• Adjusted EBITDA improved by $25.6 million year-over-year to ($5.6 million).
• Increased full-year 2025 revenue guidance to $1.26 billion (82% annual growth).
• Increased full-year 2025 Adjusted EBITDA guidance to $5 million, a $110 million improvement over 2024.
• Completed an upsized offering of $750 million in 0.75% convertible senior notes, enhancing balance sheet and reducing interest expense.
• Cash and marketable securities improved by approximately $70 million to $293.0 million.
• Clinical volumes re-accelerated, growing 30% in the quarter, delivering over 212,000 NGS tests.
• Expanded AI-powered clinical tools with Tempus Next in breast cancer and Tempus One integration into EHR systems.
• Introduced Tempus xM liquid biopsy assay for immunotherapy response monitoring.
• Expanded exclusive collaboration with Personalis to include colorectal cancer for NeXT Personal MRD.
• Reached a significant database milestone with over 40 million clinical patient records and over 350 petabytes of connected clinical and molecular data.

Negatives

• The company still reported a net loss of ($42.8 million) for the quarter.
• Adjusted EBITDA remains negative at ($5.6 million) for the quarter, despite significant improvement.

Risks

• Risks related to the intended use of Tempus products and services.
• Uncertainties regarding Tempus's financial performance.
• Challenges in attracting and retaining customers and partners.
• Difficulties in managing growth and future expenses.
• Impact of competition and new market entrants.
• Compliance with new laws, regulations, and executive actions, including evolving regulations in the artificial intelligence space.
• Ability to maintain, protect, and enhance Tempus's intellectual property.
• Ability to attract and retain qualified team members and key personnel.
• Ability to repay or refinance outstanding debt, or to access additional financing.
• Risks associated with future acquisitions, divestitures, or investments, including the ability to realize expected benefits from the acquisition of Ambry Genetics and Deep 6 AI.
• Potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, trade tensions and tariffs, and war or other armed conflict.
• General risks and uncertainties described in Tempus's Form 10-K for the year ended December 31, 2024, and Form 10-Q for the quarter ended June 30, 2025.

Future Outlook

Tempus AI is increasing its full-year 2025 guidance, now expecting approximately $1.26 billion in revenue for the consolidated business, representing about 82% annual growth. The company also anticipates achieving positive Adjusted EBITDA of $5 million for full-year 2025, which marks an improvement of approximately $110 million over 2024.

Management Comments

• "The business is performing well with revenues and margins growing faster than expected, contributing to our continued improvement in adjusted EBITDA on a year-over-year basis."
• "We saw significant re-acceleration of our clinical volumes which grew 30% in the quarter, as we delivered more than 212,000 NGS tests."
• "Combined with our continued leadership in AI and progress toward building the largest foundation model in oncology, we're hitting our stride as we approach our 10th anniversary."

Industry Context

Tempus AI operates at the intersection of artificial intelligence, precision medicine, and genomics, a rapidly evolving sector within healthcare. The company's strong revenue growth, particularly in genomics and data services, aligns with the increasing adoption of AI-driven solutions for personalized patient care and drug discovery. Its focus on building a large multimodal data library and AI-enabled tools positions it to capitalize on the growing demand for data-driven insights in oncology and other therapeutic areas. The expansion of its clinical tools and database milestones reflect a broader industry trend towards integrating advanced analytics and AI into clinical workflows and research.

Comparison to Industry Standards

• No specific comparable companies, projects, or results were mentioned in the filing for direct assessment against global benchmarks.

Related Party Transactions

• Related party revenue of $15,908 thousand for the three months ended June 30, 2025, and $16,539 thousand for the six months ended June 30, 2025.
• Related party asset of $2,535 thousand (current portion) and $22,465 thousand (less current portion) as of June 30, 2025.
• Related party payable of $25,000 thousand as of June 30, 2025.
• Related party deferred revenue of $36,685 thousand as of June 30, 2025.

Stakeholder Impact

• **Shareholders:** Positive impact due to strong revenue growth, significant improvement in profitability, increased full-year guidance, and strengthened financial flexibility through the convertible notes offering, which could lead to increased share price.
• **Customers (Physicians & Patients):** Positive impact through expanded AI-powered clinical tools (Tempus Next, Tempus One), new liquid biopsy assays (Tempus xM), and broader data integration, leading to enhanced decision support and personalized patient care.
• **Employees:** Positive impact due to company growth and expansion, potentially leading to job stability and opportunities.
• **Creditors:** Positive impact from the company's improved financial health and the successful offering of convertible senior notes, which enhances the balance sheet and reduces interest expense.

Next Steps

• A conference call and webcast will be held on Friday, August 8, 2025, at 8:00 a.m. Eastern Time to discuss the results.
• The company is approaching its 10-year anniversary, reflecting on a decade of innovation and collaboration.

Key Dates

Recommendation

The filing presents exceptionally strong financial results, including nearly 90% year-over-year revenue growth and a dramatic reduction in net loss, alongside a significant improvement in Adjusted EBITDA. The upward revision of full-year guidance for both revenue and Adjusted EBITDA signals robust future performance and a clear path to profitability. Strategic operational advancements, such as expanded AI tools and a growing data footprint, reinforce the company's competitive advantage in the precision medicine space. The successful convertible notes offering further strengthens the balance sheet. These factors collectively indicate strong momentum and significant upside potential for the stock.

Keywords

AI, precision medicine, genomics, oncology, healthcare technology, diagnostics, liquid biopsy, EHR integration, data licensing, NGS testing, biotechnology, medical technology